Mounting Popularity of Wireless and Handheld Devices to Support Uptake of e-Prescription Systems

Trends indicate a growing acceptance of the concept of e-prescription across Europe. Healthcare in Europe is becoming increasingly digitised as the healthcare delivery system undergoes tremendous change. However, electronic technology that is transforming various areas of business is yet to be fully explored in the area of medication prescription with challenges related to the poor basic level of automation and technical barriers to the ease of use first needing to be overcome. Nevertheless, the rising popularity of wireless and handheld devices are set to promote the adoption of e-prescription systems. Such systems are set to offer considerable benefits, while exhibiting limited drawbacks, spurring their uptake.

New analysis from Frost & Sullivan, European Markets for e-Prescription Systems including integrated and stand-alone e-prescription systems, finds that the market was worth $95.4 million in 2008 and estimates this to reach $449.7 million in 2015.

"Having experienced tremendous growth in the United States, e-prescription is on course to be accepted by the healthcare system in Europe," notes Frost & Sullivan Research Analyst Jayapradha T E. "With an increase in the acceptance of integrated healthcare solutions, government initiatives and the need to reduce medical errors caused by paper prescriptions, the e-prescription market is expected to carve a niche for itself in the global healthcare arena."

There is a mounting need to ensure greater mobility for both patients and health professionals. This has resulted in attempts to modernise healthcare IT systems through the electronic exchange of data, improved networking and benchmarking at the EU level. This, in turn, requires the effective integration of economic, organisational and clinical information across the healthcare spectrum.

"The drive towards enhanced healthcare mobility, reduced costs and improved efficiency, paralleled by an emphasis on patient safety and service quality, is having a direct positive impact on the e-prescription systems market in Europe," states Jayapradha.

However, resistance among prescribers to adopt the technology of e-prescription has hampered the delivery of such systems in the healthcare industry. PhysiciansÂ’ discomfort with software products has to be overcome. Though there are reports that explain the benefits of e-prescription, there is only limited empirical data and evidence to support such claims.

"A major challenge relates to the reluctance of prescribers to use e-prescription solutions," remarks Jayapradha. "Moreover, there is a lack of empirical evidence to support the benefits of e-prescription systems."

European physicians lack awareness about the advantages of e-prescription. There is a generalised view that training is required to use the system and that such training consumes a considerable amount of time. This is posing problems in the marketing of new technologies and their use in physician practices.

"Good change management and stakeholder engagement are vital to overcome the reluctance of health professionals to shift from paper-based to electronic-based prescriptions," comments Jayapradha. "There is also a need for more empirical data through research to prove the benefits reaped by existing users of e-prescription."

European Markets for e-Prescription Systems is part of the Healthcare & Life Sciences IT Growth Partnership Services programme, which also includes research in the following markets: European Medical Equipment Services Market, European market for Medical Display Monitors, Archiving Requirements for Image Management, European PACS Market and European Integrated National/Regional Health Information Networks. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

For further information, please visit:
http://www.healthcareit.frost.com

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...